Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pioglitazone - Takeda

Drug Profile

Pioglitazone - Takeda

Alternative Names: Actos; AD-4833; Glustin; PGZ; Piozone; U 72107; U 72107A; U 72107E; Zactos

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer Duke University Medical Center; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd; Novo Nordisk; Piramal Enterprises; Takeda; Takeda Pharmaceuticals USA; Tianjin Takeda; Zinfandel Pharmaceuticals
  • Class Antihyperglycaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis
  • Discontinued Alzheimer's disease; Atherosclerosis; Multiple sclerosis

Most Recent Events

  • 01 Feb 2018 Discontinued - Phase-III for Alzheimer's disease in United Kingdom, Australia, Germany, Italy, Switzerland and USA (PO)
  • 25 Jan 2018 Takeda and Zinfandel Pharmaceuticals terminates the phase III TOMMORROW trial based on a planned interim futility analysis in Alzheimer's disease in USA, United Kingdom, Germany, Italy, Switzerland and Australia (PO) (NCT01931566)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top